Ibrutinib May Boost Efficacy of CAR T Cells

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2018-167
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Development of CAR T Cells Designed to Improve Antitumor Efficacy and Safety

Pharmacology and Therapeutics
Pharmacology
2017English

Engineering CAR-T Cells

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2017English

Clinical Trials of Dual-Target CAR T Cells, Donor-Derived CAR T Cells, and Universal CAR T Cells for Acute Lymphoid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2019English

Anti-Car-Engineered T Cells for Epitope-Based Elimination of Autologous CAR T Cells

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Targeting Glioblastoma With CAR T Cells

Cancer Discovery
Oncology
2017English

Tracing the Path of CAR T Cells

Cancer Discovery
Oncology
2017English

Improved Survival of CAR‐T and Tumor‐specific T Cells Caused by Anti‐PD‐1 scFv‐producing CAR‐T Cells

Cancer Science
Cancer ResearchMedicineOncology
2019English

CAR T Cells for Acute Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy